• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by United Therapeutics Corporation (Amendment)

    6/10/24 12:15:17 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $UTHR alert in real time by email
    SC 13G/A 1 tv0001-unitedtherapeuticscor.htm SCHEDULE 13G/A unitedtherapeuticscorp

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 12)*

    Name of issuer:  United Therapeutics Corp

    Title of Class of Securities:  Common Stock

    CUSIP Number:  91307C102

    Date of Event Which Requires Filing of this Statement: May 31, 2024

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  91307C102

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    27,403

    7.  SOLE DISPOSITIVE POWER

    4,620,191

    8.  SHARED DISPOSITIVE POWER

    67,202

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,687,393

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    10.57%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    United Therapeutics Corp

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    1000 Spring Street
    Silver Spring, MD 20910

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    91307C102

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  June 10, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $UTHR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $UTHR

    DatePrice TargetRatingAnalyst
    6/2/2025$405.00Overweight
    Cantor Fitzgerald
    4/25/2025Overweight → Equal Weight
    Wells Fargo
    4/21/2025$314.00Underperform → Neutral
    BofA Securities
    7/11/2024$310.00 → $321.00Overweight → Equal-Weight
    Morgan Stanley
    2/12/2024$213.00 → $215.00Sell → Neutral
    Goldman
    2/5/2024$330.00Outperform
    Leerink Partners
    12/8/2023$309.00Overweight
    Wells Fargo
    12/6/2022$320.00Buy
    UBS
    More analyst ratings

    $UTHR
    SEC Filings

    View All

    SEC Form 144 filed by United Therapeutics Corporation

    144 - UNITED THERAPEUTICS Corp (0001082554) (Subject)

    9/9/25 4:25:39 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    United Therapeutics Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - UNITED THERAPEUTICS Corp (0001082554) (Filer)

    9/2/25 7:00:49 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    United Therapeutics Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - UNITED THERAPEUTICS Corp (0001082554) (Filer)

    8/1/25 5:17:30 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UTHR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP & GENERAL COUNSEL Mahon Paul A exercised 11,000 shares at a strike of $135.42 and sold $4,237,281 worth of shares (11,000 units at $385.21) (SEC Form 4)

    4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)

    9/5/25 4:30:18 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRESIDENT AND COO Benkowitz Michael exercised 22,500 shares at a strike of $139.13 and sold $9,396,837 worth of shares (22,500 units at $417.64) (SEC Form 4)

    4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)

    9/4/25 7:53:47 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Causey Christopher exercised 3,000 shares at a strike of $132.30 and sold $1,269,630 worth of shares (3,000 units at $423.21) (SEC Form 4)

    4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)

    9/2/25 4:39:02 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UTHR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    United Therapeutics Corporation Announces TETON-2 Pivotal Study of Tyvaso® Meets Primary Endpoint for the Treatment of Idiopathic Pulmonary Fibrosis

    Positive results were observed across all subgroups Study meets several key secondary endpoints with statistical significance United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that its TETON-2 study evaluating the use of nebulized Tyvaso® (treprostinil) Inhalation Solution for the treatment of idiopathic pulmonary fibrosis (IPF) met its primary efficacy endpoint of demonstrating improvement in absolute forced vital capacity (FVC) relative to placebo. Tyvaso demonstrated superiority over placebo for the change in absolute FVC by 95.6 mL (Hodges-Lehmann estimate, p <0.0001) from baseline to week 52 in patients with IPF. Benefits of Tyvaso were

    9/2/25 7:00:00 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    United Therapeutics Corporation to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

    United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that James Edgemond, Chief Financial Officer and Treasurer, will provide an overview and update on the company's operations during a fireside chat session at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York. The session will take place on Monday, September 8, 2025, from 3:20 p.m. to 3:55 p.m., Eastern Standard Time, and can be accessed via a live webcast on the United Therapeutics website at https://ir.unither.com/events-and-presentations. An archived, recorded version of the session will be available approximately 24 hours after the session ends and can be accessed for 90

    8/29/25 7:00:00 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy

    DANBURY, Conn. and BOSTON, Aug. 27, 2025 (GLOBE NEWSWIRE) --  MannKind Corporation (NASDAQ:MNKD) today announced that United Therapeutics Corporation (NASDAQ:UTHR) has exercised its option—granted under the companies' 2018 license and collaboration agreement—to develop a second dry powder inhalation therapy. The original agreement, which led to U.S. FDA approval of Tyvaso DPI in May 2022, included an option for United Therapeutics to expand the license to include additional active ingredients. Under the terms of the expanded agreement, MannKind will formulate a second investigational molecule using its proprietary Technosphere® platform, and United Therapeutics will conduct precli

    8/27/25 8:05:00 AM ET
    $MNKD
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UTHR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on United Therapeutics with a new price target

    Cantor Fitzgerald initiated coverage of United Therapeutics with a rating of Overweight and set a new price target of $405.00

    6/2/25 8:55:47 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    United Therapeutics downgraded by Wells Fargo

    Wells Fargo downgraded United Therapeutics from Overweight to Equal Weight

    4/25/25 8:31:30 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    United Therapeutics upgraded by BofA Securities with a new price target

    BofA Securities upgraded United Therapeutics from Underperform to Neutral and set a new price target of $314.00

    4/21/25 8:09:51 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UTHR
    Leadership Updates

    Live Leadership Updates

    View All

    IM Therapeutics Announces Appointment of Jonathan Rigby to Board of Directors

    WOBURN, Mass.--(BUSINESS WIRE)--ImmunoMolecular Therapeutics, Inc. (“IM Therapeutics”), a clinical stage company developing personalized therapies for autoimmune disease, announced today that Jonathan Rigby has joined its Board of Directors. Mr. Rigby brings extensive company building and pipeline development experience in autoimmune and other diseases. IM Therapeutics is developing small molecule oral genetic medicines targeting specific human leukocyte antigen (HLA) variants known to play a strong role in autoimmune diseases. The Company’s lead drug candidate, IMT-002, is in Phase 1b clinical trials in type 1 diabetes (T1D). Patients in the study were preselected for HLA-DQ8, the

    1/27/21 8:00:00 AM ET
    $CLGN
    $UTHR
    $XERS
    Industrial Specialties
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $UTHR
    Financials

    Live finance-specific insights

    View All

    United Therapeutics Corporation to Report Second Quarter 2025 Financial Results Before Market Open on Wednesday, July 30, 2025

    United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its second quarter 2025 financial results before the market opens on Wednesday, July 30, 2025. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a public webcast Wednesday, July 30, 2025, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics' website at https://ir.unither.com/events-and-presentations. A rebroadcast of the webcast will be available for one year and can be accessed at the same location. United Therapeutics: Enabling Inspiration At United Therapeutics, our vision and mis

    7/16/25 7:00:00 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    United Therapeutics Corporation Reports First Quarter 2025 Financial Results

    United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2025. Total revenues in the first quarter of 2025 grew 17 percent year-over-year to $794.4 million, compared to $677.7 million in the first quarter of 2024. "2025 is off to a tremendous start as we reported yet another quarter of record revenue," said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. "Beyond the continued execution of our foundational wave of growth in the commercial business, throughout the balance of the year we'll progress our innovation and revolution waves of growth with the readout

    4/30/25 6:30:00 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    United Therapeutics Corporation to Report First Quarter 2025 Financial Results Before Market Open on Wednesday, April 30, 2025

    United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its first quarter 2025 financial results before the market opens on Wednesday, April 30, 2025. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a public webcast Wednesday, April 30, 2025, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics' website at https://ir.unither.com/events-and-presentations. A rebroadcast of the webcast will be available for one year and can be accessed at the same location. United Therapeutics: Enabling Inspiration At United Therapeutics, our vision and missi

    4/16/25 7:00:00 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UTHR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by United Therapeutics Corporation

    SC 13G/A - UNITED THERAPEUTICS Corp (0001082554) (Subject)

    11/8/24 4:30:29 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by United Therapeutics Corporation

    SC 13G - UNITED THERAPEUTICS Corp (0001082554) (Subject)

    10/16/24 1:03:48 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by United Therapeutics Corporation (Amendment)

    SC 13G/A - UNITED THERAPEUTICS Corp (0001082554) (Subject)

    6/10/24 12:15:17 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care